Key result
Therapeutic angiogenesis using bone marrow-derived mononuclear cells downregulated PAI-1 levels in patients with critical limb ischemia over 6 months.
Why the study?
Does therapeutic angiogenesis with bone marrow-derived mononuclear cells improve fibrinolytic parameters in patients with critical limb ischemia?
Does therapeutic angiogenesis with bone marrow-derived mononuclear cells improve fibrinolytic parameters in patients with critical limb ischemia?
Therapeutic angiogenesis with bone marrow-derived mononuclear cells downregulates PAI-1 levels in patients with critical limb ischemia, suggesting a systemic improvement in fibrinolysis.
Answers are grounded in this paper and cite their sources.
May indicate fibrinolytic benefit in critical limb ischemia; leaves open effects on clinical outcomes.
The mechanisms of fibrinolysis have been suggested to be linked to the pathogenesis of peripheral artery disease. The impact of therapeutic angiogenesis on the parameters of fibrinolysis was studied in critical limb ischemia (CLI). CLI patients (N = 29) and blood donors as controls (N = 29) were enrolled. Bone marrow (600 ± 50 ml) was centrifuged (3200g, 20 min, 22°C), bone marrow-derived mononuclear cells (100-120 ml) were separated by Optipress I and implanted into the ischemic limb using intramuscular injections. ELISA was employed for the assessment of plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) levels. Patients were followed-up prior to the procedure and after 1, 3 and 6 months. All stage-IV patients (N = 22) had ischemic lesions. The lesions resolved in 10 patients. Five patients underwent major amputation; they all were stage-IV. Ischemic lesions persisted in seven patients beyond 6 months. The t-PA levels were higher in patients compared with the healthy controls both at baseline (P < 0.01) and after 6 months (P < 0.05). No significant changes were observed in the t-PA levels during the follow-up. PAI-1 was higher in patients than in the healthy individuals at baseline (P < 0.001) and at month 1 (P < 0.05). However, no difference in PAI-1 levels between the patients and the healthy individuals was found after 3 and 6 months. The PAI-1 levels were significantly downregulated during the follow-up compared with the baseline (P < 0.0001). Therapeutic angiogenesis for the CLI downregulates PAI-1 levels, thus having a systemic effect on fibrinolysis.
No takes yet. Share an insight, caveat, or question.
Chudý et al. (2013) studied Critical limb ischemia (n=58). Therapeutic angiogenesis (intramuscular injection of bone marrow-derived mononuclear cells) vs. Healthy blood donors was evaluated on Plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) levels (p=<0.0001). Therapeutic angiogenesis using bone marrow-derived mononuclear cells downregulated PAI-1 levels in patients with critical limb ischemia over 6 months.
Synapse has enriched 10 related papers. Consider them for comparative context: